Skip to main content
Theraclion SA logo

Theraclion SA — Investor Relations & Filings

Ticker · ALTHE ISIN · FR0010120402 LEI · 9695007X7HA7A1GCYD29 PA Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2014-07-23 Capital/Financing Update
Country FR France
Listing PA ALTHE

About Theraclion SA

https://www.theraclion.com/?_ga=2.14878…

Theraclion SA is a medical device company specializing in the development and marketing of non-invasive therapeutic solutions using High-Intensity Focused Ultrasound (HIFU). The company's technology, known as echotherapy, provides a non-surgical alternative for tissue ablation. Its flagship product, SONOVEIN®, is a robotic solution for the non-invasive treatment of varicose veins. The system uses external ultrasound beams to ablate the target vein without incisions, catheters, or sedation, allowing for immediate patient recovery. Theraclion also developed ECHOPULSE®, a system for the treatment of thyroid nodules and breast fibroadenomas. The company's core focus is on providing precise, non-invasive treatments that reduce risks and recovery time compared to traditional surgical procedures.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Capital/Financing Update Classification · 99% confidence The document is a press release dated July 23, 2014, announcing that Theraclion received a €900 K€ financing/repayable advance from Bpifrance for a joint development project (TUCE) with SuperSonic Imagine. The core subject is the acquisition of funding for capital development and innovation, which directly aligns with the definition of 'Capital/Financing Update'. It is not an Annual Report (10-K), an Earnings Release (ER), or a formal regulatory filing like a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ). Therefore, the appropriate code is CAP.
2014-07-23 French
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Earnings Release Classification · 98% confidence The document is a press release dated July 7, 2014, announcing the company's revenue ('Chiffre d'affaires') for the first half of 2014 ('1er semestre 2014'). It highlights key financial figures (483 K€) and provides commentary from the CEO regarding recent IPO success and commercial progress. This format—a brief, periodic announcement of key financial results—aligns perfectly with the definition of an Earnings Release (ER). It is not a comprehensive report (like 10-K or IR), nor is it a transcript or a general regulatory filing. H1 2014
2014-07-07 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and references Article 223-16 of the AMF General Regulation. It provides a table showing the total number of shares and voting rights as of June 30, 2014. This content directly relates to the structure of the company's capital and voting rights, which aligns with the definition of a Major Shareholding Notification (MRQ) or potentially a specific regulatory filing. However, given the specific focus on the total number of shares and voting rights, it is a routine disclosure related to capital structure changes or ownership thresholds. Since there is no specific code for 'Total Voting Rights Disclosure', I must evaluate the closest fit. It is not a dividend notice (DIV), director dealing (DIRS), or share issue (SHA). It is a periodic disclosure about the capital base. In many regulatory contexts, these monthly capital structure updates are often grouped under general regulatory filings or sometimes under major shareholding notifications if they cross thresholds, but here it is a mandatory monthly disclosure of the total base. Given the options, this type of mandatory periodic disclosure about the capital base and voting rights is most closely related to 'Major Shareholding Notification' (MRQ) as it pertains to the underlying structure that dictates shareholding significance, or potentially 'Regulatory Filings' (RNS) as a catch-all. Since it is a specific, recurring disclosure about the capital base, and not a change in a specific shareholder's stake (MRQ), the most appropriate general category for a specific, non-standard report is 'Regulatory Filings' (RNS). However, looking closely at the definitions, 'MRQ' is for 'Notification of changes in significant share ownership levels (crossing thresholds)'. This document reports the *total* base, which is a prerequisite for assessing thresholds. If this were a US filing, it might be an 8-K item 3.02 or similar. Given the French context and the specific nature of reporting total voting rights monthly, it is a highly specific regulatory disclosure. Since 'RNS' is the fallback for miscellaneous filings, and this doesn't fit the other specific financial/corporate action codes well, RNS is the safest classification, although it is a very specific type of regulatory report. Re-evaluating: This is a mandatory disclosure of the total share capital and voting rights, often required monthly in European markets. It is a fundamental regulatory disclosure. I will classify it as RNS (Regulatory Filings) as it is a specific regulatory report that doesn't map perfectly to the other defined categories like ER, IR, or CAP.
2014-07-03 French
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Report Publication Announcement Classification · 99% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ" (Semi-annual balance sheet of the liquidity contract) and details the current holdings (shares and cash) in a liquidity account managed by a broker (Portzamparc) as of June 30, 2014. This type of regular reporting on market-making or liquidity provision arrangements, which involves tracking assets related to market stability or trading, is a specific financial disclosure. It is not a full annual report (10-K), an earnings release (ER), or a standard interim report (IR). It is a specific regulatory disclosure related to market operations. Given the options, this specialized report on a liquidity contract does not fit perfectly into the standard categories like DIV, NAV, or CAP. However, it is a specific financial/regulatory update. Since it is a formal, periodic report detailing the status of a financial arrangement, and not just an announcement of a report (RPA), it is best classified as a specialized financial disclosure. Given the available codes, 'NAV' (Net Asset Value) is sometimes used broadly for fund-related asset reporting, but this is about a liquidity contract. 'RNS' (Regulatory Filings) is the fallback for miscellaneous regulatory announcements. Since this is a specific, periodic report on a contractual arrangement impacting market operations, and no better fit exists, RNS is the most appropriate general regulatory filing category, although it is highly specific content.
2014-07-03 French
Communicated under the obligation to provide permanent information / Other communications
Earnings Release Classification · 99% confidence The document is a press release dated May 20th, 2014, announcing the first two non-invasive treatments of benign breast tumors in the U.S. using the Echopulse device, which is part of a feasibility study leading to potential FDA marketing approval (PMA). It discusses clinical trial progress, market potential, and company background. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement of business/clinical progress. Since it is a general announcement about company operations and clinical milestones, and does not fit the specific categories like M&A (TAR), Director's Dealing (DIRS), or Capital Change (CAP), it falls best under the general Regulatory Filings/Announcements category (RNS), as it is a formal communication to the market about a significant operational step, often required for listing compliance, but not fitting a more specific financial report type. The length is substantial (over 10,000 characters), ruling out RPA based on the 'Menu vs Meal' rule, and it is not a transcript (CT) or a presentation (IP). FY 2014
2014-05-20 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated May 20, 2014, announcing that Theraclion has completed its first two non-invasive treatments of benign breast tumors in the US at the University of Virginia. It details the progress of a clinical study required for FDA approval (PMA) and mentions the device (Echopulse®) is already CE marked in the EU. The text is an announcement about clinical progress and regulatory steps (IDE, PMA, FDA), not a formal periodic financial report (like 10-K or IR), an earnings release (ER), or a proxy statement. It is a general corporate update regarding clinical trials and market expansion strategy. Since it is a specific announcement about clinical/regulatory progress that doesn't fit the other specific categories (like M&A, Capital Change, Dividend), it falls best under the general 'Regulatory Filings' (RNS) category, which often captures press releases detailing significant operational or regulatory milestones that aren't covered by other specific codes.
2014-05-20 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.